Professor Frédéric Amant, PhD and MD, received his medical degree from the University of Leuven (KU Leuven), Belgium in 1992, completed his specialty training as an obstetrician/gynecologist in 1998, and his subspecialty training in gynecologic oncology in 2000.
Frédéric Amant is currently professor at the KU Leuven, Belgium and University of Amsterdam, the Netherlands. Professor Amant co-founded the European Network for Individualized Treatment of Endometrial Cancer (ENITEC), a task force within the European Society of Gynecologic Oncology (ESGO). He also heads the International Network on Cancer, Infertility and Pregnancy (INCIP), also within ESGO, and is recognized as a world authority on cancer in pregnancy. Furthermore, he founded the Patient Derived Tumor Xenograft Platform (Trace) at KU Leuven and is a member of the European consortium on xenografts EurOPDX.
Professor Amant was involved in MOMATEC I, a prospective study on endometrial cancer combining serum and endometrial biopsy biomarkers and clinical data. This international collaborative study initiated in Bergen is a source of valuable new data focusing on predictive markers for lymph node involvement and survival. Today, his Amsterdam group supports the continuation of this collaboration in the frame work of MOMATEC II. The second Bergen initiated study tailors surgical treatment of endometrial cancer on the basis of biomarkers, and needs more international support. In addition, he is open to share the TRACE experience and models with CCBIO, allowing the usage of excellent preclinical models to validate experiments. Eleven models of different tumor types are available and can be shared. In addition, through EurOPDX, more models are accessible. Together with CCBIO based Erica Werner he continues to further develop
ENITEC which is the sole uterus focused research group worldwide and continues to grow. Here, collaborations will be updated and new proposals discussed.